FDA Detailed Expanded Use of Remote Regulatory Assessments in New Guidance and CMS Proposed Updates to Remote Therapeutic Monitoring in 2023 Fee Schedule
FDA is releasing a draft guidance on the expanded use of remote regulatory assessments (RRAs) and how the FDA generally intends this tool, once finalized, to be incorporated consistently across [...]